SLNO Soleno Therapeutics, Inc. Common Stock : Bullish and Bearish Analyst Opinions
Sentiment & Price
▼
Sentiment Gauge
0
Bull
0
Bear
0
Watch
Bull 50%
Bear 50%
Price & Sentiment
Loading chart...
Recent News
Top Views ▼
No recent news for SLNO
No theses available
Feed
15:07
Apr 09
Apr 09
Adding capital to an existing, high-conviction long position in SLNO rather than seeking new setups.
HIGH
01:26
Apr 07
Apr 07
Buyout announcement creates a clear, immediate arbitrage opportunity to go long SLNO as it will trade up toward the acquisition price.
MED
23:07
Mar 31
Mar 31
The user expresses relief or resilience regarding their positions in ABVX and SLNO.
15:02
Mar 31
Mar 31
The author suggests SLNO is poised for a potential breakout due to its association with successful M&A activity.
14:10
Mar 31
Mar 31
Author expects SLNO to be acquired next (following APLS deal) because it is the only remaining drug option in its niche after a competitor's drug was halted for safety.
HIGH
14:07
Mar 31
Mar 31
Following the APLS buyout, SLNO is a prime acquisition target with a monopoly in its indication after a competitor's drug was halted, trading at a low enterprise value relative to its projected free cash flow.
HIGH
17:20
Mar 27
Mar 27
The trader is aggressively selling puts on ABVX and SLNO, indicating a bullish outlook.
16:51
Mar 24
Mar 24
The author is aggressively accumulating shares of SLNO at current price levels.
18:29
Mar 15
Mar 15
The author provides a routine portfolio update detailing additions, reductions, and closures across various biotech stocks.
05:40
Feb 26
Feb 26
Shorting the stock based on a significant downward price target revision from a sell-side analyst, implying a negative change in the fundamental outlook.
MED
About SLNO Analyst Coverage
Buzzberg tracks SLNO (Soleno Therapeutics, Inc. Common Stock) across 4 sources. 9 bullish vs 1 bearish calls from 4 analysts. Sentiment: predominantly bullish (80%). 10 total trade ideas tracked.